There’s just nothing to stop it, and it’s going to be a lot of fun.” Martha highlighted Medtronic’s Evolut FX+ transcatheter aortic valve replacement (TAVR) system as a key innovation in the ...

Barclays said clinicians have demonstrated a strong preference for BEV TAVR (balloon-expandable transcatheter aortic valve replacement). "AVR’s DurAVR valve system is on track to be the second ...

Barclays said clinicians have demonstrated a strong preference for BEV TAVR (balloon-expandable transcatheter aortic valve replacement), which are self-expanding. "AVR’s DurAVR valve system is ...

As the first Medtronic self-expanding TAVR system approved in China, the Evolut PRO system approval is based on clinical data from more than 32,000 patients, which showed high survival ...

Barclays said clinicians have demonstrated a strong preference for BEV TAVR (balloon-expandable transcatheter aortic valve replacement). “AVR’s DurAVR valve system is on track to be the second balloon ...

That was again due to increased adoption of the Evolut FX+ TAVR system, the PulseSelect Pulsed Field Ablation, and Coronary products. Medtronic's Neuroscience segment generated nearly $2.5 billion ...

The firm's analysis highlighted the potential market impact of Anteris's DurAVR valve system, which is anticipated to become the second balloon-expandable transcatheter aortic valve replacement (TAVR) ...

Anteris Technologies' DurAVR system expected to capture 4%-5% of the U.S. TAVR market by 2030, driven by strong clinician preference for BEV Analyst forecasts DurAVR's superior hemodynamics ...